Timothy G Berger, MD

Offices

2 locations · University of California San Francisco · 1,780 clinicians in this group

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

9 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Berger’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026

California Medical Board record

Licence G32599 · Current

Licensed to practise in California · since 1976 · expires 2029-02-28 · University of Texas Southwestern Medical School at Dallas.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

American Board of Dermatology - Dermatology
American Board of Dermatology - Dermatopathology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at UCSF Medical Center

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	4.9 (3.79 to 6.02) · 7,590 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	12.8 (11.3 to 14.4) · 2,019 cases	Worse	Jan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	139.4 (110.22 to 168.58) · 452 cases	Better	Jul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.622	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.626	Better	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.491	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.8 (0.7 to 1) · 2,336 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.24 (0.58 to 1.9) · 4,689 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	1.05 (0.89 to 1.2)	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.9 · 89 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	7.5 · 85 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	10.1 · 132 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.6 · 454 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 618 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	9.6 · 380 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.7 · 5,000 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.22 (0.06 to 0.38) · 15,965 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.2 (0.05 to 0.35) · 17,859 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.85 (0 to 1.83) · 4,184 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2 (1.1 to 2.9) · 6,516 cases	No different	Jul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths	7.35 (4.49 to 10.21) · 3,989 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5 (3.22 to 6.77) · 4,087 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.95 (0.74 to 3.15) · 2,034 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.95 (0.63 to 1.28) · 15,431 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	4 · 399 cases	None	Apr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.899	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.689	No different	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	1.224	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16 · 156 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20 · 564 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	60.3 · 160 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-9.7 · 550 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	44.1 · 660 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.8 · 667 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.7 (4.8 to 6.7) · 2,019 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	6 · 421 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	10.5 · 53 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	20 · 107 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	13.9 (11.3 to 17.1) · 3,247 cases	No different	Jan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at UCSF Medical Center

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at UCSF Medical Center

Room was "always" clean	71%
Nurses "always" communicated well	80%
Doctors "always" communicated well	80%
Staff "always" explained	61%
Yes, staff "did" give patients this information	88%
Yes, staff "did" give patients information about help after discharge	87%
Doctors "always" explained things so they could understand	74%
Doctors "always" listened carefully	78%
Doctors "always" treated them with courtesy and respect	86%
Patients who gave a rating of "9" or "10" (high)	76%
Staff "always" explained new medications	75%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	78%
Nurses "always" treated them with courtesy and respect	86%
"Always" quiet at night	50%
"YES", patients would definitely recommend the hospital	81%
Staff "always" explained possible side effects	46%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$29,479

Medicare paid this office $29,479 for 149 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Return visit (30+ min)	97	$16,061	$79
New patient visit (45+ min)	22	$2,436	$111
Short return visit (20+ min)	30	$2,407	$57
Destruction of skin growth, 1-14 growths	12	$1,873	$65
Injection into skin growth, more than 7 growths	11	$1,250	$40

See all 11 services

Sort by

Every Original Medicare service billed

Return visit (30+ min)	97	$16,061	$79
New patient visit (45+ min)	22	$2,436	$111
Short return visit (20+ min)	30	$2,407	$57
Destruction of skin growth, 1-14 growths	12	$1,873	$65
Injection into skin growth, more than 7 growths	11	$1,250	$40
Destruction of precancer skin growth, 1 growth	19	$1,165	$45
Injection into skin growth, 1-7 growths	18	$713	$23
Punch biopsy, first skin growth	17	$709	$39
Short return visit	15	$605	$28
Biopsy of related skin growth, first growth	13	$355	$27
Destruction of precancer skin growth, 2-14 growths	17	$157	$2

Procedures Medicare counted

Sort by

Procedure volume Medicare published

Removal of skin lesions	66	More than 73% of doctors who do this
Skin biopsy	27	More than 65% of doctors who do this

Procedures year by year

Procedures billed to Original Medicare by year
Procedure	2019	2020	2021	2022	2023	2024
Destruction of precancer skin growth, 2-14 growths	189	111	192	196	167	89
Destruction of precancer skin growth, 1 growth	58	37	62	67	43	26
Punch biopsy, first skin growth	45	28	38	25	14	18
Injection into skin growth, 1-7 growths	30	14	18	32	21	31
Destruction of skin growth, 1-14 growths	17	19	26	21	32	29
Biopsy of related skin growth, first growth	29	12	25	43	20	13

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

149 Original Medicare patients in 2024. Average age 75 · Women 52% · Also on Medicaid 13% · Health risk score 1.44. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 60% · Chronic kidney disease 23% · Depression 20% · Diabetes 17% · Coronary heart disease 17% · Cancer 16% · Atrial fibrillation 15% · COPD 14% · Heart failure 12% · Dementia 9% · Stroke 7%.

The office billed $260,987, Medicare allowed $39,730 and paid $29,479; for 566 services of 25 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	149	566	75	1.44	$260,987	$29,479
2023	191	679	75	1.35	$285,701	$30,636
2022	258	955	75	1.27	$422,932	$47,934
2021	209	879	75	1.33	$370,610	$44,348
2020	179	594	75	1.20	$222,839	$22,103
2019	252	883	74	1.20	$319,146	$30,431
2018	279	985	74	1.24	$342,969	$34,416
2017	305	1,067	74	1.30	$335,027	$35,098
2016	279	1,083	73	1.36	$334,382	$34,341
2015	273	1,064	73	1.32	$346,315	$37,648
2014	305	1,085	73	1.10	$350,120	$38,703
2013	363	1,227	72	1.16	$331,390	$40,100

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 9 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	116	$15,960	$77
Short return visit (20+ min)	45	$3,263	$54
New patient visit (45+ min)	30	$2,847	$95
Destruction of skin growth, 1-14 growths	23	$1,830	$57
Destruction of precancer skin growth, 1 growth	35	$1,773	$41
Injection into skin growth, 1-7 growths	14	$491	$23
Biopsy of related skin growth, first growth	15	$430	$22
Punch biopsy, first skin growth	14	$405	$29
Destruction of precancer skin growth, 2-14 growths	27	$266	$2

2022: 13 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	148	$23,722	$84
Short return visit (20+ min)	72	$5,787	$54
New patient visit (45+ min)	48	$5,273	$110
Destruction of precancer skin growth, 1 growth	44	$3,017	$45
Injection into skin growth, more than 7 growths	16	$1,512	$39
Destruction of skin growth, 1-14 growths	19	$1,118	$53
New patient visit (30+ min)	15	$1,102	$73
Biopsy of related skin growth, first growth	34	$1,059	$25
Punch biopsy, first skin growth	23	$908	$36
Injection into skin growth, 1-7 growths	20	$777	$24
Short return visit	13	$564	$30
Destruction of precancer skin growth, 2-14 growths	30	$337	$2
Biopsy of related skin growth, each additional growth	11	$254	$18

2021: 13 services

Sort by

Original Medicare services billed in 2021

Return visit (30+ min)	115	$19,730	$85
Short return visit (20+ min)	78	$7,407	$57
New patient visit (45+ min)	41	$5,014	$122
Destruction of precancer skin growth, 1 growth	34	$2,880	$46
Destruction of skin growth, 1-14 growths	22	$1,612	$62
Punch biopsy, first skin growth	35	$1,446	$38
New patient visit (30+ min)	16	$1,198	$75
Short return visit	13	$843	$31
Biopsy of related skin growth, first growth	21	$571	$23
Injection into skin growth, 1-7 growths	14	$425	$24
Punch biopsy, each additional skin growth	13	$422	$23
Destruction of precancer skin growth, 2-14 growths	26	$360	$2
Biopsy of related skin growth, each additional growth	11	$241	$19

2020: 11 services

Sort by

Original Medicare services billed in 2020

Short return visit (20+ min)	109	$9,341	$43
Return visit (30+ min)	31	$3,575	$67
New patient visit (30+ min)	32	$2,107	$66
Destruction of precancer skin growth, 1 growth	27	$1,741	$47
Destruction of skin growth, 1-14 growths	15	$1,247	$66
Punch biopsy, first skin growth	27	$1,131	$40
New patient visit (15+ min)	14	$586	$42
Short return visit	24	$518	$19
Biopsy of related skin growth, first growth	12	$341	$28
Injection into skin growth, 1-7 growths	12	$243	$17
Destruction of precancer skin growth, 2-14 growths	23	$222	$2

2019: 12 services

Sort by

Original Medicare services billed in 2019

Short return visit (20+ min)	153	$11,473	$43
Return visit (30+ min)	38	$3,721	$70
New patient visit (30+ min)	48	$3,035	$63
Destruction of precancer skin growth, 1 growth	39	$2,541	$44
Punch biopsy, first skin growth	41	$1,763	$39
Short return visit	38	$1,355	$21
Destruction of skin growth, 1-14 growths	14	$1,041	$61
New patient visit (15+ min)	27	$937	$35
Injection into skin growth, 1-7 growths	19	$760	$25
Biopsy of related skin growth, first growth	26	$707	$24
Injection into skin growth, more than 7 growths	12	$575	$36
Destruction of precancer skin growth, 2-14 growths	26	$391	$2

2018: 11 services

Sort by

Original Medicare services billed in 2018

Short return visit (20+ min)	151	$10,318	$42
Return visit (30+ min)	77	$8,325	$64
New patient visit (30+ min)	57	$3,566	$63
Destruction of precancer skin growth, 1 growth	35	$2,736	$44
Biopsy of single growth of skin and/or tissue	53	$2,530	$36
Short return visit	40	$1,114	$19
Injection into skin growth, 1-7 growths	23	$998	$27
New patient visit (15+ min)	24	$914	$38
Injection into skin growth, more than 7 growths	12	$618	$39
Destruction of precancer skin growth, 2-14 growths	29	$395	$2
Biopsy of each additional growth of skin and/or tissue	13	$349	$22

2017: 9 services

Sort by

Original Medicare services billed in 2017

Short return visit (20+ min)	182	$14,242	$42
Return visit (30+ min)	45	$4,458	$65
Destruction of precancer skin growth, 1 growth	53	$3,727	$47
Biopsy of single growth of skin and/or tissue	67	$2,900	$37
New patient visit (30+ min)	41	$2,560	$62
New patient visit (15+ min)	53	$2,090	$39
Short return visit	69	$1,688	$20
Injection into skin growth, 1-7 growths	25	$1,010	$25
Destruction of precancer skin growth, 2-14 growths	44	$454	$2

2016: 10 services

Sort by

Original Medicare services billed in 2016

Short return visit (20+ min)	156	$11,917	$43
Return visit (30+ min)	47	$5,331	$60
Destruction of precancer skin growth, 1 growth	51	$3,588	$43
Biopsy of single growth of skin and/or tissue	73	$3,170	$34
New patient visit (30+ min)	51	$3,078	$60
Short return visit	81	$2,199	$21
New patient visit (15+ min)	21	$903	$43
Biopsy of each additional growth of skin and/or tissue	16	$550	$22
Destruction of precancer skin growth, 2-14 growths	40	$498	$2
Injection into skin growth, 1-7 growths	11	$359	$22

2015: 10 services

Sort by

Original Medicare services billed in 2015

Short return visit (20+ min)	170	$13,454	$42
Return visit (30+ min)	56	$6,394	$66
Destruction of precancer skin growth, 1 growth	60	$3,584	$44
New patient visit (30+ min)	55	$3,503	$64
Biopsy of single growth of skin and/or tissue	69	$3,320	$38
Short return visit	63	$1,715	$20
Injection into skin growth, 1-7 growths	19	$713	$26
New patient visit (15+ min)	15	$631	$42
Destruction of precancer skin growth, 2-14 growths	41	$392	$2
Biopsy of each additional growth of skin and/or tissue	13	$360	$21

2014: 10 services

Sort by

Original Medicare services billed in 2014

Short return visit (20+ min)	184	$13,731	$43
Return visit (30+ min)	77	$7,879	$66
New patient visit (30+ min)	59	$3,727	$63
Destruction of precancer skin growth, 1 growth	49	$3,562	$46
Biopsy of single growth of skin and/or tissue	67	$3,419	$38
Short return visit	74	$1,744	$20
New patient visit (15+ min)	29	$1,210	$42
Injection into skin growth, 1-7 growths	14	$635	$22
Destruction of precancer skin growth, 2-14 growths	40	$464	$2
Biopsy of each additional growth of skin and/or tissue	12	$424	$21

2013: 11 services

Sort by

Original Medicare services billed in 2013

Short return visit (20+ min)	216	$13,549	$42
Return visit (30+ min)	54	$4,860	$68
Destruction of precancer skin growth, 1 growth	65	$4,454	$50
New patient visit (30+ min)	67	$4,370	$65
Biopsy of single growth of skin and/or tissue	84	$3,628	$39
Short return visit	93	$2,309	$20
New patient visit (15+ min)	44	$1,707	$39
Destruction of precancer skin growth, 2-14 growths	54	$1,187	$4
Destruction of skin growth, 1-14 growths	12	$1,038	$69
Injection into skin growth, 1-7 growths	20	$792	$24
Biopsy of each additional growth of skin and/or tissue	15	$558	$21

Drugs they prescribed that Part D paid

$878,138

Pharmacies billed $878,138 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 1,104) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

902 generic and 202 brand-name prescriptions · $878,138 in drug cost · 43 antibiotic prescriptions to 14 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Dupixent	78	$296,995	$3,808
Dupixent	63	$276,363	$4,387
Rinvoq	15	$99,259	$6,617
Adbry	19	$74,425	$3,917
Tacrolimus	46	$9,790	$213

See all 28 drugs

Sort by

Every Part D drug this clinician prescribed

Dupixent	78	$296,995	$3,808
Dupixent	63	$276,363	$4,387
Rinvoq	15	$99,259	$6,617
Adbry	19	$74,425	$3,917
Tacrolimus	46	$9,790	$213
Clobetasol Propionate	64	$3,181	$50
Acitretin	13	$2,538	$195
Gabapentin	122	$1,689	$14
Hydroxychloroquine Sulfate	63	$1,666	$26
Methotrexate	42	$1,099	$26
Fluocinonide	17	$1,017	$60
Triamcinolone Acetonide	60	$996	$17
Doxycycline Hyclate	23	$964	$42
Pentoxifylline	15	$817	$54
Mirtazapine	12	$812	$68
Naltrexone	12	$644	$54
Metronidazole	15	$580	$39
Pregabalin	31	$506	$16
Mycophenolate Mofetil	11	$473	$43
Clindamycin Phosphate	16	$398	$25
Ketoconazole	21	$320	$15
Prednisone	41	$271	$7
Hydrocortisone	27	$153	$6
Montelukast	12	$151	$13
Mexiletine	11	$150	$14
Mupirocin	15	$131	$9
Amoxicillin	11	$48	$4
Finasteride	17	$44	$3

Year by year

Sort by

Part D prescribing by year

2024	1,104	182	0% (0)	18%	$878,138
2023	1,217	204	0% (0)	None	$872,194
2022	1,343	208	None	None	$748,481
2021	1,318	188	0% (0)	14%	$636,898
2020	1,434	204	0% (0)	12%	$444,044
2019	1,344	221	None	None	$250,880
2018	1,616	252	None	None	$309,468
2017	1,512	257	None	12%	$316,267
2016	1,322	234	None	None	$173,493
2015	1,224	241	0% (0)	15%	$228,426
2014	1,350	275	None	None	$227,819
2013	1,202	256	0% (0)	None	$208,568

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 30 drugs

Sort by

Part D drugs prescribed in 2023

Dupixent	109	$438,439	$4,022
Dupixent	53	$190,928	$3,602
Otezla	12	$48,635	$4,053
Tacrolimus	45	$10,017	$223
Clobetasol Propionate	66	$5,160	$78
Gabapentin	132	$3,583	$27
Calcipotriene	23	$2,932	$127
Fluocinonide	31	$2,841	$92
Triamcinolone Acetonide	51	$2,248	$44
Mexiletine	15	$1,692	$113
Metronidazole	29	$1,679	$58
Hydroxychloroquine Sulfate	36	$1,640	$46
Doxycycline Hyclate	19	$1,611	$85
Methotrexate	40	$1,540	$38
Naltrexone	28	$1,318	$47
Pregabalin	47	$1,296	$28
Clindamycin Phosphate	15	$1,154	$77
Mirtazapine	18	$1,112	$62
Pentoxifylline	28	$965	$34
Betamethasone Dipropionate	11	$916	$83
Dutasteride	11	$901	$82
Doxepin	17	$596	$35
Betamethasone Diprop Augmented	11	$528	$48
Prednisone	40	$407	$10
Ketoconazole	25	$403	$16
Hydrocortisone	33	$356	$11
Montelukast	14	$356	$25
Finasteride	14	$293	$21
Amoxicillin	11	$204	$19
Folic Acid	12	$61	$5

2022: 31 drugs

Sort by

Part D drugs prescribed in 2022

Dupixent	115	$491,209	$4,271
Dupixent	11	$44,980	$4,089
Clobetasol Propionate	72	$6,604	$92
Tacrolimus	33	$6,007	$182
Pimecrolimus	13	$5,417	$417
Gabapentin	188	$5,058	$27
Doxycycline Hyclate	24	$3,051	$127
Hydroxychloroquine Sulfate	49	$2,881	$59
Fluocinonide	26	$2,876	$111
Triamcinolone Acetonide	52	$2,847	$55
Naltrexone	30	$2,378	$79
Methotrexate	51	$2,089	$41
Metronidazole	20	$2,037	$102
Betamethasone Diprop Augmented	15	$1,653	$110
Pregabalin	65	$1,598	$25
Calcipotriene	13	$1,519	$117
Clindamycin Phosphate	14	$1,483	$106
Mexiletine	18	$812	$45
Halobetasol Propionate	11	$789	$72
Pentoxifylline	13	$689	$53
Doxepin	23	$606	$26
Hydrocortisone	54	$548	$10
Prednisone	54	$547	$10
Dutasteride	13	$501	$39
Ketoconazole	19	$397	$21
Mirtazapine	11	$363	$33
Finasteride	16	$253	$16
Mupirocin	12	$112	$9
Doxycycline Monohydrate	11	$99	$9
Amoxicillin	13	$82	$6
Folic Acid	13	$62	$5

2021: 26 drugs

Sort by

Part D drugs prescribed in 2021

Dupixent	111	$429,328	$3,868
Dupixent	25	$94,675	$3,787
Clobetasol Propionate	67	$12,079	$180
Tacrolimus	20	$5,566	$278
Pimecrolimus	12	$4,795	$400
Hydroxychloroquine Sulfate	65	$4,270	$66
Pregabalin	78	$4,113	$53
Gabapentin	209	$3,637	$17
Methotrexate	83	$3,212	$39
Fluocinonide	43	$3,156	$73
Betamethasone Dipropionate	31	$1,800	$58
Triamcinolone Acetonide	48	$1,365	$28
Betamethasone Valerate	13	$1,260	$97
Naltrexone	11	$1,010	$92
Permethrin	14	$894	$64
Lidocaine	12	$827	$69
Ketoconazole	29	$778	$27
Doxepin	17	$773	$45
Propranolol Hcl Er	16	$677	$42
Nystatin	26	$439	$17
Montelukast	23	$276	$12
Mexiletine	11	$276	$25
Hydrocortisone	22	$179	$8
Prednisone	18	$159	$9
Amoxicillin	12	$78	$7
Folic Acid	12	$48	$4

2020: 33 drugs

Sort by

Part D drugs prescribed in 2020

Dupixent	85	$265,935	$3,129
Clobetasol Propionate	81	$9,635	$119
Hydroxychloroquine Sulfate	72	$6,297	$87
Methotrexate	112	$5,802	$52
Gabapentin	243	$5,242	$22
Colchicine	17	$3,944	$232
Mycophenolate Mofetil	28	$3,905	$139
Fluocinonide	51	$3,562	$70
Betamethasone Dipropionate	37	$3,541	$96
Pregabalin	64	$3,478	$54
Tacrolimus	16	$2,963	$185
Alclometasone Dipropionate	16	$2,358	$147
Dapsone	12	$2,282	$190
Propranolol Hcl Er	28	$1,954	$70
Triamcinolone Acetonide	66	$1,811	$27
Desoximetasone	11	$1,386	$126
Valacyclovir	13	$1,314	$101
Betamethasone Valerate	14	$1,313	$94
Doxycycline Hyclate	26	$1,276	$49
Betamethasone Diprop Augmented	11	$1,200	$109
Doxepin	30	$1,004	$33
Naltrexone	14	$686	$49
Ivermectin	11	$576	$52
Ketoconazole	17	$540	$32
Clindamycin Phosphate	12	$537	$45
Pentoxifylline	14	$461	$33
Mexiletine	12	$413	$34
Propranolol	11	$386	$35
Nystatin	17	$275	$16
Montelukast	21	$185	$9
Prednisone	22	$170	$8
Hydrocortisone	22	$123	$6
Amoxicillin	13	$85	$7

2019: 28 drugs

Sort by

Part D drugs prescribed in 2019

Dupixent	29	$90,665	$3,126
Thalomid	14	$66,871	$4,776
Lyrica	22	$12,256	$557
Clobetasol Propionate	55	$6,911	$126
Methotrexate	153	$6,484	$42
Hydroxychloroquine Sulfate	53	$5,925	$112
Gabapentin	239	$5,427	$23
Betamethasone Dipropionate	38	$4,951	$130
Fluocinonide	66	$4,158	$63
Mycophenolate Mofetil	47	$4,023	$86
Tacrolimus	15	$3,545	$236
Desoximetasone	18	$2,097	$116
Pregabalin	15	$1,822	$121
Triamcinolone Acetonide	53	$1,658	$31
Halobetasol Propionate	15	$1,642	$109
Claravis	11	$1,431	$130
Desonide	11	$1,226	$111
Doxycycline Hyclate	27	$1,207	$45
Azathioprine	11	$1,066	$97
Doxepin	28	$845	$30
Valacyclovir	17	$836	$49
Ketoconazole	29	$781	$27
Prednisone	43	$494	$11
Hydrocortisone	22	$476	$22
Ivermectin	14	$330	$24
Nystatin	21	$204	$10
Mupirocin	15	$182	$12
Amoxicillin	13	$134	$10

2018: 38 drugs

Sort by

Part D drugs prescribed in 2018

Thalomid	21	$113,316	$5,396
Dupixent	21	$76,181	$3,628
Clobetasol Propionate	56	$14,735	$263
Elidel	14	$7,777	$556
Lyrica	12	$6,455	$538
Doxepin	43	$5,976	$139
Hydroxychloroquine Sulfate	70	$5,900	$84
Mycophenolate Mofetil	69	$5,729	$83
Fluocinonide	70	$5,696	$81
Betamethasone Dipropionate	42	$5,275	$126
Methotrexate	150	$5,215	$35
Gabapentin	214	$4,186	$20
Tacrolimus	13	$3,989	$307
Claravis	14	$3,568	$255
Betamethasone Diprop Augmented	12	$3,178	$265
Desonide	16	$1,751	$109
Triamcinolone Acetonide	79	$1,724	$22
Desoximetasone	16	$1,688	$105
Doxycycline Hyclate	32	$1,408	$44
Azathioprine	16	$1,318	$82
Lidocaine	14	$1,000	$71
Mexiletine	16	$999	$62
Valacyclovir	29	$982	$34
Prednisone	84	$781	$9
Mirtazapine	18	$735	$41
Nystatin	19	$639	$34
Ketoconazole	22	$569	$26
Montelukast	27	$487	$18
Ivermectin	12	$371	$31
Hydroxyzine	14	$287	$21
Nortriptyline	12	$253	$21
Hydrocortisone	39	$245	$6
Duloxetine	11	$202	$18
Amoxicillin	17	$202	$12
Ranitidine	12	$180	$15
Mupirocin	18	$151	$8
Cephalexin	16	$93	$6
Terbinafine	11	$79	$7

2017: 39 drugs

Sort by

Part D drugs prescribed in 2017

Thalomid	25	$145,094	$5,804
Dupixent	16	$46,988	$2,937
Clobetasol Propionate	76	$12,929	$170
Tacrolimus	18	$10,786	$599
Hydroxychloroquine Sulfate	73	$9,002	$123
Fluocinonide	68	$7,660	$113
Lyrica	17	$7,593	$447
Desoximetasone	29	$7,336	$253
Doxepin	53	$6,634	$125
Claravis	12	$4,070	$339
Betamethasone Dipropionate	40	$3,229	$81
Methotrexate	85	$3,147	$37
Gabapentin	241	$3,095	$13
Mycophenolate Mofetil	32	$2,864	$90
Lidocaine	24	$2,644	$110
Doxycycline Hyclate	30	$1,455	$48
Azathioprine	20	$1,395	$70
Triamcinolone Acetonide	59	$1,366	$23
Desonide	13	$1,114	$86
Alclometasone Dipropionate	16	$1,024	$64
Prednisone	75	$819	$11
Cephalexin	13	$796	$61
Clindamycin Phosphate	11	$725	$66
Mexiletine	13	$626	$48
Valacyclovir	16	$579	$36
Hydroxyzine	14	$505	$36
Ketoconazole	16	$377	$24
Duloxetine	12	$317	$26
Pentoxifylline	13	$252	$19
Hydrocortisone	29	$177	$6
Nortriptyline	17	$173	$10
Paroxetine	14	$170	$12
Montelukast	25	$162	$6
Amoxicillin	17	$161	$9
Mirtazapine	15	$137	$9
Nystatin	14	$122	$9
Mupirocin	12	$100	$8
Terbinafine	12	$88	$7
Ranitidine	15	$71	$5

2016: 30 drugs

Sort by

Part D drugs prescribed in 2016

Clobetasol Propionate	112	$22,407	$200
Hydroxychloroquine Sulfate	72	$9,262	$129
Desoximetasone	32	$8,757	$274
Fluocinonide	61	$8,713	$143
Lidocaine	24	$6,036	$251
Elidel	13	$5,713	$439
Desonide	24	$3,163	$132
Doxepin	42	$2,187	$52
Gabapentin	140	$2,099	$15
Methotrexate	72	$2,071	$29
Mycophenolate Mofetil	24	$1,962	$82
Fluorouracil	13	$1,677	$129
Triamcinolone Acetonide	68	$1,659	$24
Dapsone	14	$1,519	$108
Metronidazole	12	$1,369	$114
Valacyclovir	37	$1,340	$36
Doxycycline Hyclate	26	$1,295	$50
Clindamycin Phosphate	21	$906	$43
Mercaptopurine	11	$882	$80
Prednisone	61	$765	$13
Pentoxifylline	23	$644	$28
Ketoconazole	27	$557	$21
Mexiletine	11	$526	$48
Naltrexone	11	$448	$41
Azathioprine	11	$275	$25
Hydrocortisone	29	$201	$7
Nortriptyline	15	$169	$11
Amoxicillin	16	$138	$9
Montelukast	17	$136	$8
Ranitidine	11	$69	$6

2015: 29 drugs

Sort by

Part D drugs prescribed in 2015

Thalomid	15	$72,333	$4,822
Clobetasol Propionate	115	$30,039	$261
Desoximetasone	48	$16,432	$342
Hydroxychloroquine Sulfate	75	$10,641	$142
Elidel	22	$10,011	$455
Acitretin	19	$7,696	$405
Desonide	30	$4,703	$157
Fluocinonide	32	$4,701	$147
Mycophenolate Mofetil	30	$3,646	$122
Doxycycline Hyclate	25	$3,163	$127
Metronidazole	14	$2,336	$167
Gabapentin	121	$1,686	$14
Triamcinolone Acetonide	60	$1,663	$28
Clindamycin Phosphate	30	$1,594	$53
Methotrexate	56	$1,592	$28
Permethrin	11	$1,516	$138
Valacyclovir	35	$1,269	$36
Prednisone	75	$942	$13
Dapsone	22	$896	$41
Duloxetine	12	$852	$71
Doxepin	19	$750	$39
Clotrimazole	22	$741	$34
Hydroxyzine	14	$697	$50
Ketoconazole	28	$568	$20
Cephalexin	17	$194	$11
Amoxicillin	12	$191	$16
Nortriptyline	16	$152	$10
Mupirocin	12	$127	$11
Paroxetine	12	$66	$6

2014: 31 drugs

Sort by

Part D drugs prescribed in 2014

Xolair	18	$43,978	$2,443
Desoximetasone	87	$28,737	$330
Elidel	40	$16,266	$407
Clobetasol Propionate	153	$15,909	$104
Acitretin	14	$14,835	$1,060
Doxycycline Hyclate	31	$5,321	$172
Desonide	33	$5,039	$153
Mycophenolate Mofetil	48	$4,639	$97
Fluocinonide	47	$3,507	$75
Permethrin	21	$3,364	$160
Methotrexate	38	$2,976	$78
Metronidazole	21	$2,524	$120
Gabapentin	167	$1,962	$12
Triamcinolone Acetonide	67	$1,708	$25
Lidocaine	13	$1,498	$115
Valacyclovir	17	$1,168	$69
Clindamycin Phosphate	16	$971	$61
Prednisone	69	$890	$13
Doxycycline Monohydrate	16	$812	$51
Hydroxychloroquine Sulfate	35	$746	$21
Hydroxyzine	24	$572	$24
Dapsone	14	$567	$41
Cephalexin	29	$471	$16
Doxepin	20	$413	$21
Nystatin	14	$398	$28
Dexamethasone	13	$355	$27
Ketoconazole	16	$295	$18
Spironolactone	11	$276	$25
Acyclovir	16	$83	$5
Hydrocortisone	11	$77	$7
Paroxetine	12	$71	$6

2013: 23 drugs

Sort by

Part D drugs prescribed in 2013

Desoximetasone	70	$18,611	$266
Clobetasol Propionate	152	$9,334	$61
Elidel	21	$6,323	$301
Doxycycline Hyclate	36	$6,200	$172
Mycophenolate Mofetil	47	$5,866	$125
Fluocinonide	61	$3,637	$60
Methotrexate	52	$3,601	$69
Desonide	29	$2,411	$83
Triamcinolone Acetonide	78	$2,027	$26
Metronidazole	16	$1,993	$125
Hydroxyzine	34	$1,430	$42
Gabapentin	71	$1,291	$18
Dapsone	14	$1,093	$78
Clindamycin Phosphate	13	$793	$61
Hydroxychloroquine Sulfate	44	$678	$15
Dexamethasone	12	$577	$48
Prednisone	63	$433	$7
Doxepin	34	$401	$12
Econazole Nitrate	11	$369	$34
Ketoconazole	14	$297	$21
Cephalexin	15	$237	$16
Pentoxifylline	13	$199	$15
Mupirocin	11	$151	$14

Money from drug and device companies

$38,388 in 2025

Sort by

Industry payments by year

2025	5	17	$36,230	$38,388
2024	2	8	$30,744	$31,180
2023	5	39	$88,377	$111,319
2022	4	23	$44,527	$60,231
2021	1	1	$2,480	$2,480
2020	1	7	$9,828	$11,070
2019	2	9	$13,085	$15,040

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Galderma Laboratories L.P.	Nemluvio	$12,581	4 payments Consulting for Nemluvio · 2025-12-18 · $7,225 Meals for Nemluvio · 2025-12-03 · $133 Consulting for Nemluvio · 2025-09-27 · $5,180 Travel for Nemluvio · 2025-09-27 · $43
Genzyme	Dupixent	$12,129	8 payments Meals for Dupixent · 2025-12-04 · $30 Meals · 2025-08-25 · $23 Meals · 2025-02-04 · $9 Meals for Dupixent · 2025-02-03 · $89 Paid to speak or teach for Dupixent · 2025-02-03 · $10,675 Travel for Dupixent · 2025-02-03 · $272 Travel for Dupixent · 2025-02-03 · $534 Travel for Dupixent · 2025-02-03 · $497
Regeneron Healthcare Solutions	None	$11,175	3 payments Paid to speak or teach · 2025-03-18 · $10,675 Travel · 2025-03-07 · $307 Travel · 2025-03-07 · $193
Novartis Pharmaceuticals	None	$2,475	1 payment Consulting · 2025-04-22 · $2,475
Blueprint Medicines	None	$29	1 payment Meals · 2025-05-16 · $29

See all 17 published payments

Sort by

Every published payment

Galderma Laboratories L.P.	Consulting · 2025-12-18	Nemluvio	$7,225
Genzyme	Meals · 2025-12-04	Dupixent	$30
Galderma Laboratories L.P.	Meals · 2025-12-03	Nemluvio	$133
Galderma Laboratories L.P.	Consulting · 2025-09-27	Nemluvio	$5,180
Galderma Laboratories L.P.	Travel · 2025-09-27	Nemluvio	$43
Genzyme	Meals · 2025-08-25	None	$23
Blueprint Medicines	Meals · 2025-05-16	None	$29
Novartis Pharmaceuticals	Consulting · 2025-04-22	None	$2,475
Regeneron Healthcare Solutions	Paid to speak or teach · 2025-03-18	None	$10,675
Regeneron Healthcare Solutions	Travel · 2025-03-07	None	$307
Regeneron Healthcare Solutions	Travel · 2025-03-07	None	$193
Genzyme	Meals · 2025-02-04	None	$9
Genzyme	Meals · 2025-02-03	Dupixent	$89
Genzyme	Paid to speak or teach · 2025-02-03	Dupixent	$10,675
Genzyme	Travel · 2025-02-03	Dupixent	$272
Genzyme	Travel · 2025-02-03	Dupixent	$534
Genzyme	Travel · 2025-02-03	Dupixent	$497

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $31,180

Sort by

Payments by company in 2024

Genzyme	Dupixent	$29,899	6 payments Consulting for Dupixent · 2024-12-13 · $14,945 Meals for Dupixent · 2024-12-13 · $43 Travel for Dupixent · 2024-12-13 · $372 Meals for Dupixent · 2024-12-13 · $21 Consulting for Dupixent · 2024-12-07 · $3,416 Consulting for Dupixent · 2024-04-19 · $11,102
Regeneron Healthcare Solutions	None	$1,281	2 payments Paid to speak or teach · 2024-08-08 · $427 Paid to speak or teach · 2024-04-04 · $854

2023: $111,319

Sort by

Payments by company in 2023

Genzyme	Dupixent	$53,673	24 payments Meals for Dupixent · 2023-12-19 · $27 Paid to speak or teach for Dupixent · 2023-11-05 · $500 Paid to speak or teach for Dupixent · 2023-11-05 · $250 Travel for Dupixent · 2023-11-03 · $102 Meals for Dupixent · 2023-11-03 · $101 Meals for Dupixent · 2023-11-03 · $31 Meals for Dupixent · 2023-11-03 · $25 Meals for Dupixent · 2023-11-03 · $48 Meals for Dupixent · 2023-11-03 · $30 Consulting for Dupixent · 2023-11-03 · $11,368 Paid to speak or teach · 2023-08-16 · $2,496 Meals for Dupixent · 2023-06-21 · $50 Travel for Dupixent · 2023-06-21 · $3,488 Travel for Dupixent · 2023-06-21 · $50 Consulting for Dupixent · 2023-06-21 · $15,341 Travel for Dupixent · 2023-06-21 · $633 Meals for Dupixent · 2023-06-21 · $75 Meals for Dupixent · 2023-06-21 · $28 Travel · 2023-06-21 · $50 Meals · 2023-06-21 · $28 Meals · 2023-06-21 · $75 Meals · 2023-06-21 · $50 Travel · 2023-06-21 · $3,488 Consulting · 2023-06-21 · $15,341
Sanofi-Aventis U.S.	Dupixent	$44,891	6 payments Paid to speak or teach for Dupixent · 2023-10-21 · $28,003 Travel for Dupixent · 2023-10-21 · $9,093 Travel for Dupixent · 2023-10-21 · $1,525 Meals for Dupixent · 2023-10-21 · $686 Travel for Dupixent · 2023-10-21 · $1,633 Paid to speak or teach for Dupixent · 2023-02-18 · $3,951
Regeneron Healthcare Solutions	None	$9,706	6 payments Paid to speak or teach · 2023-10-19 · $713 Paid to speak or teach · 2023-10-19 · $7,487 Travel · 2023-10-17 · $335 Travel · 2023-10-14 · $360 Travel · 2023-08-19 · $407 Travel · 2023-08-08 · $405
Regeneron Pharmaceuticals	Dupixent	$2,928	1 payment Consulting for Dupixent · 2023-02-10 · $2,928
LEO Pharma	Adbry	$120	2 payments Education · 2023-11-06 · $25 Meals for Adbry · 2023-07-29 · $95

2022: $60,231

Sort by

Payments by company in 2022

Sanofi-Aventis U.S.	Dupixent	$37,861	5 payments Travel for Dupixent · 2022-11-11 · $12,851 Meals for Dupixent · 2022-11-11 · $560 Travel for Dupixent · 2022-11-11 · $1,318 Paid to speak or teach for Dupixent · 2022-11-11 · $23,048 Meals for Dupixent · 2022-11-11 · $84
Regeneron Healthcare Solutions	None	$11,957	11 payments Paid to speak or teach · 2022-10-18 · $7,487 Travel · 2022-10-13 · $241 Travel · 2022-10-13 · $64 Travel · 2022-10-13 · $9 Travel · 2022-10-13 · $9 Meals · 2022-10-13 · $18 Travel · 2022-10-13 · $32 Travel · 2022-09-03 · $351 Paid to speak or teach · 2022-05-24 · $1,783 Paid to speak or teach · 2022-03-15 · $891 Paid to speak or teach · 2022-02-25 · $1,070
Genzyme	Dupixent	$10,377	6 payments Consulting for Dupixent · 2022-05-01 · $366 Consulting for Dupixent · 2022-05-01 · $9,882 Meals for Dupixent · 2022-05-01 · $31 Travel for Dupixent · 2022-05-01 · $36 Travel for Dupixent · 2022-05-01 · $32 Meals · 2022-01-16 · $30
Janssen Scientific Affairs	Tremfya	$36	1 payment Meals for Tremfya · 2022-07-23 · $36

2021: $2,480

Sort by

Payments by company in 2021

Regeneron Healthcare Solutions	Dupixent	$2,480	1 payment Consulting for Dupixent · 2021-08-27 · $2,480

2020: $11,070

Sort by

Payments by company in 2020

Regeneron Healthcare Solutions	None	$11,070	7 payments Paid to speak or teach · 2020-10-06 · $1,404 Paid to speak or teach · 2020-04-23 · $1,053 Paid to speak or teach · 2020-01-22 · $7,371 Travel · 2020-01-21 · $171 Travel · 2020-01-21 · $183 Travel · 2020-01-17 · $400 Travel · 2020-01-15 · $488

2019: $15,040

Sort by

Payments by company in 2019

Regeneron Healthcare Solutions	Dupixent	$14,921	8 payments Travel for Dupixent · 2019-09-23 · $608 Paid to speak or teach · 2019-09-18 · $7,046 Paid to speak or teach for Dupixent · 2019-09-18 · $5,033 Meals · 2019-09-17 · $104 Travel · 2019-09-17 · $509 Travel · 2019-09-13 · $310 Travel · 2019-06-28 · $307 Paid to speak or teach for Dupixent · 2019-01-14 · $1,007
AbbVie	Humira	$118	1 payment Meals for Humira · 2019-02-28 · $118

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Kiniksa Pharmaceuticals International, plc · A Phase 2a/B, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Kpl-716 in Reducing Pruritis in Subjects With Prurigo Nodularis · 2024	Their institution	$11,643
Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2019	This clinician	$2,524

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 74.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1124079181
Licence: CA G32599California G32599: Current · expires 2029-02-28
Trained: University of Texas Southwestern Medical School at Dallas, 1975 · 51 years ago
Group: University of California San Francisco
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Medicaid ID: CA 00G325990
Taxonomy: Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0900X (207ND0900X)
Mailing address: 1635 Divisadero Street, Suite 625, Box 1821, San Francisco, CA, 94143
NPI first listed: 2006-05-15
NPI last updated: 2008-06-10

This is when the NPI record was last certified, not a medical board exam.